ITGAV and myocardial infarction: The CD51+bMSC treatment had more benefits for cardiac healing in mice with MI than did CD51−bMSCs after intravenous transplantation, and the effects of the retained CD51+bMSCs retained in the hearts might be associated with the anti-inflammatory capacity.